Pharma firm Laurus Labs has received tentative approval from the United States Food and Drug Administration (USFDA) for Tenofovir/Lamivudine/Dolutegravir (TLD) 300/300/50mg Fixed Dose Combination (FDC) drug. It will be available in the generic form in low and middle income countries.
About:
The U.S. Department of Health and Human Services Panel as well as WHO recommend TLD as one of the preferred first line regimen for the treatment of people living with HIV.
Given its multitude of benefits, including TLD's improved tolerability and higher resistance barrier, a concentrated effort is underway to accelerate TLD's introduction in countries supported by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR).
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
